Sai Parenteral's (NSE:SAIPARENT) Other Stockholders Equity: ₹1,926 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Other Stockholders Equity?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Other Stockholders Equity is ₹1,926 Mil as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Sai Parenteral's's Other Stockholders Equity for the quarter that ended in Sep. 2025 was ₹1,926 Mil.

Sai Parenteral's's quarterly Other Stockholders Equity increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹982 Mil) and increased from Mar. 2025 (₹982 Mil) to Sep. 2025 (₹1,926 Mil).

Sai Parenteral's's annual Other Stockholders Equity stayed the same from Mar. 2023 (₹0 Mil) to Mar. 2024 (₹0 Mil) but then increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹982 Mil).

Sai Parenteral's Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Other Stockholders Equity Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Other Stockholders Equity
0.00 0.00 981.77

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Other Stockholders Equity 0.00 0.00 981.77 1,926.41
NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹1,926 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Other Stockholders Equity of ₹1,926 Mil as of Sep. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Other Stockholders Equity too high?
Sai Parenteral's' current Other Stockholders Equity is ₹1,926 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Other Stockholders Equity compare to LLY and JNJ?
Sai Parenteral's' Other Stockholders Equity of ₹1,926 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Other Stockholders Equity is ₹1,926 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Other Stockholders Equity of ₹1,926 Mil. The current Other Stockholders Equity is ₹1,926 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Other Stockholders Equity is ₹1,926 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price